Characterization of Claim Elements as “Conventional” Results in Section 101 Subject Matter Ineligibility

July 25, 2022

Federal Circuit Holds That Claims Directed to Methods of Treating Pain in a Renally Impaired Patient Are Patent-Eligible Under Section 101

March 29, 2019

The Federal Circuit Opens the Door Wider for the Subject Matter Eligibility of Methods of Treatment, Compositions and Methods of Manufacturing

March 18, 2019

Federal Circuit holds that claims directed to diagnosing neurotransmission or developmental disorders are invalid for failing to recite patent eligible subject matter

February 11, 2019

Supreme Court Denies Sequenom’s Petition for Certiorari

July 13, 2016

Supreme Court Denies Sequenom’s Petition for Certiorari

June 28, 2016

Supreme Court Asked to Clarify Limits on Diagnostic Method Patents

April 18, 2016

Sequenom Asks the Supreme Court to Clarify the Limits on Section 101

March 25, 2016

Sandoz Requests Supreme Court Review of the Federal Circuit’s Interpretation of Biosimilar Law

February 18, 2016

Federal Circuit denies en banc review of Ariosa v. Sequenom

December 21, 2015